ID   APOC2_HUMAN             Reviewed;         101 AA.
AC   P02655; C0JYY4; Q9BS39; Q9UDE3; Q9UNK3;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   21-JUL-1986, sequence version 1.
DT   10-MAY-2017, entry version 194.
DE   RecName: Full=Apolipoprotein C-II;
DE            Short=Apo-CII;
DE            Short=ApoC-II;
DE   AltName: Full=Apolipoprotein C2;
DE   Contains:
DE     RecName: Full=Proapolipoprotein C-II;
DE              Short=ProapoC-II;
DE   Flags: Precursor;
GN   Name=APOC2; Synonyms=APC2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=3030808; DOI=10.1016/0014-5793(87)81495-3;
RA   Fojo S.S., Law S.W., Brewer H.B. Jr.;
RT   "The human preproapolipoprotein C-II gene. Complete nucleic acid
RT   sequence and genomic organization.";
RL   FEBS Lett. 213:221-226(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA].
RX   PubMed=6593704; DOI=10.1073/pnas.81.20.6354;
RA   Fojo S.S., Law S.W., Brewer H.B. Jr.;
RT   "Human apolipoprotein C-II: complete nucleic acid sequence of
RT   preapolipoprotein C-II.";
RL   Proc. Natl. Acad. Sci. U.S.A. 81:6354-6357(1984).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=6328445; DOI=10.1093/nar/12.9.3917;
RA   Sharpe C.R., Sidoli A., Shelley C.S., Lucero M.A., Shoulders C.C.,
RA   Baralle F.E.;
RT   "Human apolipoproteins AI, AII, CII and CIII. cDNA sequences and mRNA
RT   abundance.";
RL   Nucleic Acids Res. 12:3917-3932(1984).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=3558370;
RA   Das H.K., Jackson C.L., Miller D.A., Leff T., Breslow J.L.;
RT   "The human apolipoprotein C-II gene sequence contains a novel
RT   chromosome 19-specific minisatellite in its third intron.";
RL   J. Biol. Chem. 262:4787-4793(1987).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA].
RX   PubMed=2415514;
RA   Wei C.F., Tsao Y.K., Robberson D.L., Gotto A.M. Jr., Brown K.,
RA   Chan L.;
RT   "The structure of the human apolipoprotein C-II gene. Electron
RT   microscopic analysis of RNA:DNA hybrids, complete nucleotide sequence,
RT   and identification of 5' homologous sequences among apolipoprotein
RT   genes.";
RL   J. Biol. Chem. 260:15211-15221(1985).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Nickerson D.A., Smith J.D., Fullerton S.M., Clark A.G., Stengard J.H.,
RA   Salomaa V., Boerwinkle E., Sing C.F., Weiss K.M.;
RL   Submitted (SEP-2003) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NHLBI resequencing and genotyping service (RS&G);
RL   Submitted (DEC-2008) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Skeletal muscle;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 6-101, AND TISSUE SPECIFICITY.
RX   PubMed=6546757;
RA   Myklebost O., Williamson B., Markham A.F., Myklebost S.R., Rogers J.,
RA   Woods D.E., Humphries S.E.;
RT   "The isolation and characterization of cDNA clones for human
RT   apolipoprotein CII.";
RL   J. Biol. Chem. 259:4401-4404(1984).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] OF 11-101.
RX   PubMed=3014272; DOI=10.1016/0076-6879(86)28106-9;
RA   Jackson C.L., Bruns G.A.P., Breslow J.L.;
RT   "Isolation of cDNA and genomic clones for apolipoprotein C-II.";
RL   Methods Enzymol. 128:788-800(1986).
RN   [13]
RP   PROTEIN SEQUENCE OF 23-101.
RX   PubMed=6706938;
RA   Hospattankar A.V., Fairwell T., Ronan R., Brewer H.B. Jr.;
RT   "Amino acid sequence of human plasma apolipoprotein C-II from normal
RT   and hyperlipoproteinemic subjects.";
RL   J. Biol. Chem. 259:318-322(1984).
RN   [14]
RP   PROTEIN SEQUENCE OF 23-101.
RX   PubMed=194244; DOI=10.1073/pnas.74.5.1942;
RA   Jackson R.L., Baker H.N., Gilliam E.B., Gotto A.M. Jr.;
RT   "Primary structure of very low density apolipoprotein C-II of human
RT   plasma.";
RL   Proc. Natl. Acad. Sci. U.S.A. 74:1942-1945(1977).
RN   [15]
RP   PROTEIN SEQUENCE OF 29-35, PROTEOLYTIC PROCESSING, GLYCOSYLATION, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=3525527;
RA   Fojo S.S., Taam L., Fairwell T., Ronan R., Bishop C., Meng M.S.,
RA   Hoeg J.M., Sprecher D.L., Brewer H.B. Jr.;
RT   "Human preproapolipoprotein C-II. Analysis of major plasma isoforms.";
RL   J. Biol. Chem. 261:9591-9594(1986).
RN   [16]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 77-101.
RX   PubMed=11310852;
RA   Chun E.M., Park Y.J., Kang H.S., Cho H.M., Jun D.Y., Kim Y.H.;
RT   "Expression of the apolipoprotein C-II gene during myelomonocytic
RT   differentiation of human leukemic cells.";
RL   J. Leukoc. Biol. 69:645-650(2001).
RN   [17]
RP   REGION LIPOPROTEIN LIPASE COFACTOR AND REGION LIPID BINDING.
RX   PubMed=6772077; DOI=10.1111/j.1749-6632.1980.tb21300.x;
RA   Sparrow J.T., Gotto A.M. Jr.;
RT   "Phospholipid binding studies with synthetic apolipoprotein
RT   fragments.";
RL   Ann. N. Y. Acad. Sci. 348:187-211(1980).
RN   [18]
RP   FUNCTION.
RX   PubMed=2209608; DOI=10.1111/j.1432-1033.1990.tb19255.x;
RA   Bengtsson-Olivecrona G., Sletten K.;
RT   "Primary structure of the bovine analogues to human apolipoproteins
RT   CII and CIII. Studies on isoforms and evidence for proteolytic
RT   processing.";
RL   Eur. J. Biochem. 192:515-521(1990).
RN   [19]
RP   REVIEW.
RX   PubMed=22304839; DOI=10.1016/j.metabol.2011.12.002;
RA   Kei A.A., Filippatos T.D., Tsimihodimos V., Elisaf M.S.;
RT   "A review of the role of apolipoprotein C-II in lipoprotein metabolism
RT   and cardiovascular disease.";
RL   Metabolism 61:906-921(2012).
RN   [20]
RP   GLYCOSYLATION, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=23234360; DOI=10.1021/pr300963h;
RA   Halim A., Ruetschi U., Larson G., Nilsson J.;
RT   "LC-MS/MS characterization of O-glycosylation sites and glycan
RT   structures of human cerebrospinal fluid glycoproteins.";
RL   J. Proteome Res. 12:573-584(2013).
RN   [21]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [22]
RP   STRUCTURE BY NMR OF 72-101, AND REGION LIPOPROTEIN LIPASE COFACTOR.
RX   PubMed=1555583; DOI=10.1111/j.1432-1033.1992.tb16772.x;
RA   Lycksell P.-O., Oehman A., Bengtsson-Olivecrona G., Johansson L.B.-A.,
RA   Wijmenga S.S., Wernic D., Graeslund A.;
RT   "Sequence specific 1H-NMR assignments and secondary structure of a
RT   carboxy-terminal functional fragment of apolipoprotein CII.";
RL   Eur. J. Biochem. 205:223-231(1992).
RN   [23]
RP   STRUCTURE BY NMR OF 72-101.
RX   PubMed=8112221; DOI=10.1007/BF00213558;
RA   Oehman A., Lycksell P.-O., Graeslund A.;
RT   "A refined three-dimensional solution structure of a carboxy terminal
RT   fragment of apolipoprotein CII.";
RL   Eur. Biophys. J. 22:351-357(1993).
RN   [24]
RP   VARIANT AFRICA GLN-77.
RX   PubMed=3944271; DOI=10.1172/JCI112342;
RA   Menzel H.-J., Kane J.P., Malloy M.J., Havel R.J.;
RT   "A variant primary structure of apolipoprotein C-II in individuals of
RT   African descent.";
RL   J. Clin. Invest. 77:595-601(1986).
RN   [25]
RP   VARIANT SAN FRANCISCO LYS-60.
RX   PubMed=8490626; DOI=10.1093/hmg/2.1.69;
RA   Pullinger C.R., Zysow B.R., Hennessy L.K., Frost P.H., Malloy M.J.,
RA   Kanr J.P.;
RT   "Molecular cloning and characteristics of a new apolipoprotein C-II
RT   mutant identified in three unrelated individuals with
RT   hypercholesterolemia and hypertriglyceridemia.";
RL   Hum. Mol. Genet. 2:69-74(1993).
RN   [26]
RP   VARIANT THR-41.
RX   PubMed=1782747;
RA   Hegele R.A., Connelly P.W., Maguire G.F., Huff M.W., Leiter L.,
RA   Wolfe B.M., Evans A.J., Little J.A.;
RT   "An apolipoprotein CII mutation, CII Lys-19-->Thr identified in
RT   patients with hyperlipidemia.";
RL   Dis. Markers 9:73-80(1991).
RN   [27]
RP   VARIANT THR-41.
RX   PubMed=7923858;
RA   Zysow B.R., Pullinger C.R., Hennessy L.K., Farese R.V. Jr.,
RA   Ghassemzadeh M., Kane J.P.;
RT   "The apolipoprotein C-II variant apoC-II Lys-19-->Thr is not
RT   associated with dyslipidemia in an affected kindred.";
RL   Clin. Genet. 45:292-297(1994).
RN   [28]
RP   VARIANT HLPP1B WAKAYAMA ARG-48.
RX   PubMed=8323539; DOI=10.1006/bbrc.1993.1749;
RA   Inadera H., Hibino A., Kobayashi J., Kanzaki T., Shirai K., Yukawa S.,
RA   Saito Y., Yoshida S.;
RT   "A missense mutation (Trp 26-->Arg) in exon 3 of the apolipoprotein
RT   CII gene in a patient with apolipoprotein CII deficiency (apo CII-
RT   Wakayama).";
RL   Biochem. Biophys. Res. Commun. 193:1174-1183(1993).
RN   [29]
RP   VARIANT GLN-77.
RX   PubMed=10391210; DOI=10.1038/10297;
RA   Halushka M.K., Fan J.-B., Bentley K., Hsie L., Shen N., Weder A.,
RA   Cooper R., Lipshutz R., Chakravarti A.;
RT   "Patterns of single-nucleotide polymorphisms in candidate genes for
RT   blood-pressure homeostasis.";
RL   Nat. Genet. 22:239-247(1999).
CC   -!- FUNCTION: Component of chylomicrons, very low-density lipoproteins
CC       (VLDL), low-density lipoproteins (LDL), and high-density
CC       lipoproteins (HDL) in plasma. Plays an important role in
CC       lipoprotein metabolism as an activator of lipoprotein lipase. Both
CC       proapolipoprotein C-II and apolipoprotein C-II can activate
CC       lipoprotein lipase. In normolipidemic individuals, it is mainly
CC       distributed in the HDL, whereas in hypertriglyceridemic
CC       individuals, predominantly found in the VLDL and LDL.
CC       {ECO:0000269|PubMed:2209608, ECO:0000303|PubMed:22304839}.
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:3525527}.
CC   -!- TISSUE SPECIFICITY: Liver and intestine.
CC       {ECO:0000269|PubMed:6546757}.
CC   -!- PTM: Proapolipoprotein C-II is synthesized as a sialic acid
CC       containing glycoprotein which is subsequently desialylated prior
CC       to its proteolytic processing. {ECO:0000269|PubMed:3525527}.
CC   -!- PTM: Proapolipoprotein C-II, the major form found in plasma
CC       undergoes proteolytic cleavage of its N-terminal hexapeptide to
CC       generate apolipoprotein C-II, which occurs as the minor form in
CC       plasma. {ECO:0000269|PubMed:3525527}.
CC   -!- DISEASE: Hyperlipoproteinemia 1B (HLPP1B) [MIM:207750]: Autosomal
CC       recessive trait characterized by hypertriglyceridemia, xanthomas,
CC       and increased risk of pancreatitis and early atherosclerosis.
CC       {ECO:0000269|PubMed:8323539}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the apolipoprotein C2 family.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X05151; CAA28798.1; -; Genomic_DNA.
DR   EMBL; X00568; CAA25234.1; -; mRNA.
DR   EMBL; J02698; AAA98743.1; -; Genomic_DNA.
DR   EMBL; AY422955; AAQ91814.1; -; Genomic_DNA.
DR   EMBL; BT006708; AAP35354.1; -; mRNA.
DR   EMBL; FJ525875; ACN81313.1; -; Genomic_DNA.
DR   EMBL; CH471126; EAW57311.1; -; Genomic_DNA.
DR   EMBL; BC005348; AAH05348.3; -; mRNA.
DR   EMBL; M29844; AAA51743.1; -; mRNA.
DR   EMBL; M10612; AAB59380.1; -; Genomic_DNA.
DR   EMBL; AF113884; AAD28193.1; -; mRNA.
DR   CCDS; CCDS12650.1; -.
DR   PIR; A24238; LPHUC2.
DR   RefSeq; NP_000474.2; NM_000483.4.
DR   UniGene; Hs.75615; -.
DR   PDB; 1BY6; NMR; -; A=66-101.
DR   PDB; 1I5J; NMR; -; A=23-101.
DR   PDB; 1O8T; NMR; -; A=23-101.
DR   PDB; 1SOH; NMR; -; A=23-101.
DR   PDBsum; 1BY6; -.
DR   PDBsum; 1I5J; -.
DR   PDBsum; 1O8T; -.
DR   PDBsum; 1SOH; -.
DR   ProteinModelPortal; P02655; -.
DR   SMR; P02655; -.
DR   BioGrid; 106841; 3.
DR   IntAct; P02655; 4.
DR   STRING; 9606.ENSP00000466775; -.
DR   iPTMnet; P02655; -.
DR   PhosphoSitePlus; P02655; -.
DR   BioMuta; APOC2; -.
DR   DMDM; 114022; -.
DR   DOSAC-COBS-2DPAGE; P02655; -.
DR   SWISS-2DPAGE; P02655; -.
DR   EPD; P02655; -.
DR   MaxQB; P02655; -.
DR   PaxDb; P02655; -.
DR   PeptideAtlas; P02655; -.
DR   PRIDE; P02655; -.
DR   TopDownProteomics; P02655; -.
DR   DNASU; 344; -.
DR   Ensembl; ENST00000590360; ENSP00000466775; ENSG00000234906.
DR   GeneID; 344; -.
DR   KEGG; hsa:344; -.
DR   UCSC; uc060zuu.1; human.
DR   CTD; 344; -.
DR   DisGeNET; 344; -.
DR   GeneCards; APOC2; -.
DR   HGNC; HGNC:609; APOC2.
DR   HPA; HPA055877; -.
DR   MalaCards; APOC2; -.
DR   MIM; 207750; phenotype.
DR   MIM; 608083; gene.
DR   neXtProt; NX_P02655; -.
DR   OpenTargets; ENSG00000224916; -.
DR   OpenTargets; ENSG00000234906; -.
DR   Orphanet; 309020; Familial apolipoprotein C-II deficiency.
DR   PharmGKB; PA52; -.
DR   eggNOG; ENOG410J3QQ; Eukaryota.
DR   eggNOG; ENOG4111AXD; LUCA.
DR   GeneTree; ENSGT00390000007913; -.
DR   HOGENOM; HOG000034002; -.
DR   HOVERGEN; HBG050548; -.
DR   InParanoid; P02655; -.
DR   OrthoDB; EOG091G17WL; -.
DR   PhylomeDB; P02655; -.
DR   Reactome; R-HSA-174800; Chylomicron-mediated lipid transport.
DR   Reactome; R-HSA-194223; HDL-mediated lipid transport.
DR   Reactome; R-HSA-975634; Retinoid metabolism and transport.
DR   SIGNOR; P02655; -.
DR   EvolutionaryTrace; P02655; -.
DR   GeneWiki; Apolipoprotein_C2; -.
DR   GenomeRNAi; 344; -.
DR   PMAP-CutDB; P02655; -.
DR   PRO; PR:P02655; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   Bgee; ENSG00000234906; -.
DR   CleanEx; HS_APC2; -.
DR   CleanEx; HS_APOC2; -.
DR   ExpressionAtlas; P02655; baseline and differential.
DR   Genevisible; P02655; HS.
DR   GO; GO:0042627; C:chylomicron; IDA:BHF-UCL.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005769; C:early endosome; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:BHF-UCL.
DR   GO; GO:0034363; C:intermediate-density lipoprotein particle; IDA:BHF-UCL.
DR   GO; GO:0034362; C:low-density lipoprotein particle; IDA:BHF-UCL.
DR   GO; GO:0034366; C:spherical high-density lipoprotein particle; IDA:BHF-UCL.
DR   GO; GO:0034361; C:very-low-density lipoprotein particle; IDA:BHF-UCL.
DR   GO; GO:0055102; F:lipase inhibitor activity; IDA:BHF-UCL.
DR   GO; GO:0008289; F:lipid binding; IDA:BHF-UCL.
DR   GO; GO:0060230; F:lipoprotein lipase activator activity; IDA:BHF-UCL.
DR   GO; GO:0016004; F:phospholipase activator activity; IDA:BHF-UCL.
DR   GO; GO:0043274; F:phospholipase binding; IPI:BHF-UCL.
DR   GO; GO:0042803; F:protein homodimerization activity; IMP:BHF-UCL.
DR   GO; GO:0033344; P:cholesterol efflux; IDA:BHF-UCL.
DR   GO; GO:0042632; P:cholesterol homeostasis; IC:BHF-UCL.
DR   GO; GO:0034382; P:chylomicron remnant clearance; IDA:BHF-UCL.
DR   GO; GO:0034371; P:chylomicron remodeling; IC:BHF-UCL.
DR   GO; GO:0034384; P:high-density lipoprotein particle clearance; IMP:BHF-UCL.
DR   GO; GO:0016042; P:lipid catabolic process; IEA:UniProtKB-KW.
DR   GO; GO:0042157; P:lipoprotein metabolic process; TAS:Reactome.
DR   GO; GO:0042953; P:lipoprotein transport; IEA:Ensembl.
DR   GO; GO:0032375; P:negative regulation of cholesterol transport; IMP:BHF-UCL.
DR   GO; GO:0045833; P:negative regulation of lipid metabolic process; IDA:BHF-UCL.
DR   GO; GO:0048261; P:negative regulation of receptor-mediated endocytosis; IDA:BHF-UCL.
DR   GO; GO:0010916; P:negative regulation of very-low-density lipoprotein particle clearance; IDA:BHF-UCL.
DR   GO; GO:0033700; P:phospholipid efflux; IDA:BHF-UCL.
DR   GO; GO:0045723; P:positive regulation of fatty acid biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0051006; P:positive regulation of lipoprotein lipase activity; IDA:BHF-UCL.
DR   GO; GO:0010518; P:positive regulation of phospholipase activity; IDA:BHF-UCL.
DR   GO; GO:0060697; P:positive regulation of phospholipid catabolic process; IDA:BHF-UCL.
DR   GO; GO:0010898; P:positive regulation of triglyceride catabolic process; IDA:BHF-UCL.
DR   GO; GO:0010902; P:positive regulation of very-low-density lipoprotein particle remodeling; IC:BHF-UCL.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:0001523; P:retinoid metabolic process; TAS:Reactome.
DR   GO; GO:0043691; P:reverse cholesterol transport; IC:BHF-UCL.
DR   GO; GO:0070328; P:triglyceride homeostasis; IMP:BHF-UCL.
DR   GO; GO:0034370; P:triglyceride-rich lipoprotein particle remodeling; TAS:BHF-UCL.
DR   GO; GO:0034372; P:very-low-density lipoprotein particle remodeling; TAS:BHF-UCL.
DR   InterPro; IPR008019; Apo-CII.
DR   PANTHER; PTHR16566; PTHR16566; 1.
DR   Pfam; PF05355; Apo-CII; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Chylomicron; Complete proteome;
KW   Direct protein sequencing; Disease mutation; Glycoprotein; HDL;
KW   Hyperlipidemia; LDL; Lipid degradation; Lipid metabolism;
KW   Lipid transport; Polymorphism; Reference proteome; Secreted;
KW   Sialic acid; Signal; Transport; VLDL.
FT   SIGNAL        1     22       {ECO:0000269|PubMed:194244,
FT                                ECO:0000269|PubMed:6706938}.
FT   CHAIN        23    101       Proapolipoprotein C-II.
FT                                {ECO:0000269|PubMed:194244,
FT                                ECO:0000269|PubMed:6706938}.
FT                                /FTId=PRO_0000002024.
FT   CHAIN        29    101       Apolipoprotein C-II.
FT                                {ECO:0000305|PubMed:3525527}.
FT                                /FTId=PRO_0000430839.
FT   REGION       23     38       O-glycosylated at one site.
FT   REGION       66     74       Lipid binding.
FT                                {ECO:0000269|PubMed:6772077}.
FT   REGION       78    101       Lipoprotein lipase cofactor.
FT                                {ECO:0000269|PubMed:1555583,
FT                                ECO:0000269|PubMed:6772077}.
FT   VARIANT      41     41       K -> T (in dbSNP:rs120074114).
FT                                {ECO:0000269|PubMed:1782747,
FT                                ECO:0000269|PubMed:7923858}.
FT                                /FTId=VAR_000639.
FT   VARIANT      48     48       W -> R (in HLPP1B; variant Wakayama;
FT                                dbSNP:rs120074115).
FT                                {ECO:0000269|PubMed:8323539}.
FT                                /FTId=VAR_000640.
FT   VARIANT      60     60       E -> K (in San Francisco; found in
FT                                hyperlipidemic patients; dbSNP:rs5122).
FT                                {ECO:0000269|PubMed:8490626}.
FT                                /FTId=VAR_000641.
FT   VARIANT      77     77       K -> Q (in Africa; dbSNP:rs5126).
FT                                {ECO:0000269|PubMed:10391210,
FT                                ECO:0000269|PubMed:3944271}.
FT                                /FTId=VAR_000642.
FT   CONFLICT     36     36       F -> L (in Ref. 7; AAP35354 and 8;
FT                                ACN81313). {ECO:0000305}.
FT   STRAND       28     31       {ECO:0000244|PDB:1O8T}.
FT   HELIX        37     57       {ECO:0000244|PDB:1I5J}.
FT   TURN         58     61       {ECO:0000244|PDB:1I5J}.
FT   STRAND       62     64       {ECO:0000244|PDB:1I5J}.
FT   TURN         68     70       {ECO:0000244|PDB:1SOH}.
FT   STRAND       71     74       {ECO:0000244|PDB:1I5J}.
FT   TURN         75     77       {ECO:0000244|PDB:1BY6}.
FT   TURN         79     81       {ECO:0000244|PDB:1BY6}.
FT   STRAND       86     88       {ECO:0000244|PDB:1BY6}.
FT   HELIX        92     94       {ECO:0000244|PDB:1BY6}.
FT   HELIX        97     99       {ECO:0000244|PDB:1BY6}.
SQ   SEQUENCE   101 AA;  11284 MW;  51CB86FEDB174D84 CRC64;
     MGTRLLPALF LVLLVLGFEV QGTQQPQQDE MPSPTFLTQV KESLSSYWES AKTAAQNLYE
     KTYLPAVDEK LRDLYSKSTA AMSTYTGIFT DQVLSVLKGE E
//
